Healthcare Web Wire

Blog

Compounding Pharmacy Market Growth and Challenges
Compounding Pharmacy Market Trends and Growth Outlook

The global compounding pharmacy market was valued at $13.19 billion in 2023 and is expected to reach $22.91 billion by 2034, growing at a steady annual rate of 5.15% from 2024 to 2034. This growth is largely driven by the increasing demand for customized and specialized medications that cater to individual patient needs.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5338

Market Overview

The compounding pharmacy industry focuses on creating customized medications to meet the unique needs of patients. This can include patients who are allergic to certain ingredients in FDA-approved drugs, or those who need medications in forms they can easily take, such as liquid formulations instead of pills or capsules. Doctors in hospitals, clinics, and other healthcare settings may prescribe compounded medications when FDA-approved options are not suitable or necessary. In many cases, compounding helps address specific patient needs that standard treatments cannot.

Compounding Pharmacy Market Trends

In October 2024, Valor Compounding Pharmacy, a leading provider of compounded drugs, announced exciting growth and the potential for new partnerships with healthcare systems and medical practices.
In July 2024, Revelation Pharma, a national network of 503A and 503B compounding pharmacies, acquired Taylors Pharmacy. Revelation Pharma is dedicated to providing top-quality patient care and innovative solutions across its nationwide network.

Compounding Pharmacy Market Growth Driven by Personalized Medicine

As healthcare continues to evolve, the concept of personalized medicine is gaining traction, recognizing that one-size-fits-all solutions often don’t work for every patient. Compounding pharmacies are at the forefront of this shift, playing a vital role in customizing medications to suit individual needs. Advances in technology have made compounding processes safer and more accurate, while regulatory standards help ensure high-quality care.

Challenges in the Compounding Market: Risks of Poor Practices

A key challenge in the compounding pharmacy market is the potential risks posed by poor compounding practices. Since the FDA doesn’t review compounded drugs for safety, efficacy, or quality before they reach the market, there’s a risk of exposing patients to health hazards. This underscores the importance of well-trained compounding pharmacists, access to high-quality ingredients, and proper compounding facilities to ensure patient safety and product quality.

Top Companies in the Compounding Pharmacy Market
- Fagron
- Formul8
- Walgreen Co.
- MEDS Pharmacy
- Fusion Apothecary
- Aurora Compounding
- Albertsons Companies
- Apollo Clinical Pharmacy
- Galenic Laboratories Limited (Roseway Labs)
- The London Specialist Pharmacy Ltd (Specialist Pharmacy)
- JL Diekman and AQ Touchard (Fresh Therapeutics Compounding Pharmacy)
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/compounding-pharmacy-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5338

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
November 22, 2024
Bioinformatics Market Trends, Innovations and Growth
Bioinformatics Market Growth, Trends and Investment Opportunities

The bioinformatics market, valued at $11.53 billion in 2023, is expected to grow significantly, reaching $47.48 billion by 2034. This growth, with a compound annual growth rate (CAGR) of 13.73% from 2024 to 2034, is fueled by the growing demand for genomic and proteomic research, advancements in drug discovery and development, and ongoing technological innovations in the field.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5337
Bioinformatics Market Genomics and Beyond

Bioinformatics is a field that combines computational technology with biology to collect, store, analyze, and share biological data. It uses various scientific and technological methods to interpret complex biological information. This discipline is vital for understanding gene and protein expression, regulation, and evolutionary biology. In structural biology, bioinformatics helps model and simulate DNA, RNA, proteins, and molecular interactions. One of its greatest achievements is analyzing genome sequences, notably the Human Genome Project.

The growing focus on drug discovery and the identification of new drug targets is driving increased demand for bioinformatics. Advances in DNA sequencing and the expansion of research into human health and biology continue to fuel the market. Additionally, supportive government policies for research in genomics, proteomics, metabolomics, and transcriptomics are further boosting market growth.

Bioinformatics Market Trends

In September 2024, the World Health Organization (WHO) hosted a workshop to improve genomic surveillance, data sharing, and bioinformatics analysis for respiratory viruses. This initiative is aimed at enhancing the global capacity for genomic surveillance under the Global Influenza Surveillance and Response System (GISRS).

In September 2024, Almaden Genomics launched a new Data Management and Informatics Services business to help researchers, pharmaceutical companies, and biotech organizations overcome bioinformatics and computational biology challenges.

In August 2024, Inocras, Inc. announced the availability of whole genome sequencing services using the UG 100 sequencer from Ultima Genomics, Inc.

Leading Companies in the Bioinformatics Market

Illumina, Inc.

Thermo Fisher Scientific

Agilent Technologies, Inc.

Qiagen

Verge Genomics

Bio-Rad Laboratories, Inc.

Biomax Informatics

DNAnexus

Geneva Bioinformatics

Waters Corporation

Perkin Elmer, Inc.

Fios Genomics

Eurofins Scientific

Recent Insights from Industry Leaders

Li Qing, Senior Vice President and General Manager for Greater China, highlighted the rapid evolution of genomics, emphasizing the crucial role DNA sequencing plays in human health and environmental sustainability. He also shared his vision for the future, where genomics will shift from focusing on “sick care” to “health care,” aiming to enhance overall human well-being.

Recent Developments in Bioinformatics

In January 2024, researchers from Genomic England introduced a bioinformatics pipeline designed to integrate whole-genome sequencing (WGS) data from 13,880 tumors with corresponding clinical data from patients. Their study uncovered both somatic and germline DNA mutations that influence prognosis.

Also in January 2024, researchers at the Würzburg Helmholtz Institute unveiled a machine learning approach that combines data integration and AI to predict the effectiveness of CRISPR technologies with greater accuracy than previous methods.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/bioinformatics-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5337

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
November 22, 2024
AI in Cancer Diagnosis Market Overview (2024 – 2034)
AI in Cancer Diagnosis Market Growth and Opportunities (2024 – 2034)

The global market for AI in cancer diagnosis is valued at approximately USD 1.07 billion in 2024. It is projected to reach USD 2.61 billion by 2034, growing at a compound annual growth rate (CAGR) of 9.35% over the next decade.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5044

AI’s Impact on Cancer Diagnostics: Market Trends and Growth

In July 2022, the FDA released an updated list of over 178 new AI-based medical devices, bringing the total to more than 500, with more than 75% of these devices used in radiology.

Artificial intelligence (AI) is reshaping healthcare, especially in the field of cancer diagnostics, by enhancing the speed, accuracy, and efficiency of diagnoses. The AI in cancer diagnostics market is experiencing rapid growth, driven by factors such as the increasing global prevalence of cancer, the rising demand for precision medicine, and advancements in machine learning and big data analytics. This article explores the current state and future prospects of the AI in cancer diagnostics market.

AI is used in several key areas of cancer diagnosis, including medical imaging, genomics, and liquid biopsy. Of these, medical imaging holds the largest share of the market, thanks to the availability of vast imaging data, improvements in image recognition algorithms, and the growing reliance on imaging for cancer diagnosis. In terms of AI technologies, machine learning is the leading approach, making up the largest market share. Machine learning algorithms can process vast amounts of data to detect patterns that may be invisible to the human eye, greatly enhancing the accuracy and efficiency of cancer diagnoses.

Key Trends in the AI in Cancer Diagnostics Market:
- Increasing Cancer Cases: The growing number of cancer diagnoses worldwide underscores the need for faster and more accurate diagnostic tools. The World Health Organization (WHO) reported around 20 million new cancer cases in 2022, with projections suggesting this number will rise to 35 million by 2050.
- Technological Innovations: AI is revolutionizing the healthcare landscape with cutting-edge technologies that improve diagnostic capabilities and treatment options.
- Rising Investments: Cancer diagnosis and treatment are key areas of global research, with both government and private sector investments fueling market growth.
Regional Insights: AI in Cancer Diagnostics Market

North America Leads with Rising Cancer Cases

North America held the largest share of the AI in cancer diagnostics market in 2023. This dominance is driven by a combination of factors, including a high incidence of cancer, advancements in technology, and the presence of major industry players. In 2022, the American Cancer Society reported nearly 2 million new cancer cases in the United States, while Canada saw approximately 230,000 new diagnoses. Additionally, favorable government policies and regulatory approvals play a crucial role in market growth. The U.S. Food and Drug Administration (FDA) has approved several AI-assisted diagnostic tools for detecting cancers of the brain, breast, lung, prostate, skin, and thyroid.

Asia-Pacific: Fastest-Growing Market Driven by Supportive Policies

The Asia-Pacific region is expected to experience the fastest growth in the AI in cancer diagnostics market in the coming years. Key factors driving this growth include a rapidly expanding population, rising cancer cases, increasing investments and collaborations, and supportive government initiatives. The Chinese government has actively promoted AI in healthcare, targeting a 7% annual growth in R&D spending, with a focus on AI as part of its 2021-2025 Five-Year Plan. McKinsey estimates that AI could contribute around $5 billion to the economy. In India, the “Ayushman Bharat Digital Mission” supports the use of AI models, promoting a digitized healthcare ecosystem and further accelerating market development.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/ai-in-cancer-diagnosis-transforming-cancer-care

Access exclusive insight now @ https://www.towardshealthcare.com/price/5044

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
November 22, 2024
Digital Health Market Key Drivers, Trends and Emerging Opportunities
Global Digital Health Market Growth Prospects and Emerging Opportunities

The global digital health market is valued at approximately USD 335.51 billion in 2024 and is projected to reach USD 1,080.21 billion by 2034, driven by a compound annual growth rate (CAGR) of 13.1% during this period. This growth is largely fueled by the rising adoption of mobile health applications and the increasing integration of technologies like AI, IoT, and big data in healthcare.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5040

Trends Shaping the Digital Health Market

The digital health market is experiencing significant growth, driven by several key trends that are transforming the healthcare landscape:
- Mobile Health (mHealth) Apps: The growing use of mobile applications for health monitoring, remote consultations, and wellness tracking is expanding rapidly, empowering patients to take control of their health from anywhere.
- Artificial Intelligence (AI) and Machine Learning (ML): AI-driven solutions are revolutionizing diagnosis, treatment planning, and patient care by providing more accurate insights and personalized health recommendations.
- Telemedicine: Virtual healthcare services have become mainstream, offering increased access to medical professionals and reducing the burden on traditional healthcare facilities.
- Internet of Things (IoT) in Healthcare: IoT-enabled devices, such as wearables and remote monitoring tools, are providing real-time health data to patients and clinicians, enhancing patient care and outcomes.
- Big Data and Analytics: Healthcare providers are leveraging big data to analyze patient information, identify trends, and improve clinical decision-making processes.
- Interoperability and Data Security: As more healthcare systems digitize, ensuring seamless data exchange and maintaining patient data privacy and security are top priorities for providers and regulators.
Key Drivers of Digital Transformation in Healthcare

Cost efficiency has become a major factor driving digital transformation in healthcare. Before the COVID-19 pandemic, 54% of U.S. adults expressed interest in using telehealth services to save on healthcare costs. With ongoing investments in telehealth, these lower costs are expected to continue, benefiting both patients and healthcare providers.

Accessibility is another crucial driver, as the demand for more convenient healthcare options has risen, particularly among millennials. Nearly one-third of this generation finds traditional in-person visits inconvenient, prompting healthcare providers to enhance virtual care services and online health offerings to better meet their needs.

The shift toward value-based care (VBC), driven by insurers, is also reshaping the healthcare landscape. This model focuses on the quality of patient outcomes rather than the volume of services provided. Digital tools like AI-powered analytics play a vital role in this shift, helping optimize care delivery while keeping costs in check. These combined factors are significantly transforming how healthcare is delivered and experienced by patients.

Latest Announcements by Industry Leaders

Nalla Karunanithy, CEO of Aster Digital Health & E-Commerce, shared that digital transformation is the future of healthcare in the Middle East, a vision supported by the impressive growth of their platform, myAster. He emphasized that data and digital innovation are key to transforming the healthcare landscape, setting new benchmarks for convenience, quality, and patient care.

Recent Developments in the Digital Health Market

In November 2024, Max Life Insurance Company Ltd. announced a strategic partnership with Swiss Re to integrate its innovative Digital Health Underwriting (DHU) solution into its operations, marking a significant step towards improving digital health services.

In another exciting development, the George Institute for Global Health, New Delhi, launched a new digital health program in rural India. The initiative has shown promising results, reducing the risk of depression and mental health issues by 75%, combining digital tools with community outreach to create a significant impact.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/digital-health-market-is-key-to-a-healthier-future

Access exclusive insight now @ https://www.towardshealthcare.com/price/5040

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
November 22, 2024
DNA Sequencing Market Overview Trends and Growth (2024 – 2034)
DNA Sequencing Market Growth and Insights Projected Expansion from 2024 to 2034

The global DNA sequencing market was valued at $12.42 billion in 2023 and is expected to experience significant growth, reaching $107.63 billion by 2034. This growth is driven by a robust compound annual growth rate (CAGR) of 21.69% between 2024 and 2034. Key factors contributing to this expansion include rising demand for genomics research, advancements in sequencing technologies, and increased investments in the field.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5336

DNA Sequencing Market Trends Key Developments and Insights

The DNA sequencing market is experiencing rapid growth, driven by several key trends:
- Technological Advancements: Continuous improvements in sequencing technologies, such as next-generation sequencing (NGS), are enhancing accuracy, speed, and affordability, making DNA sequencing more accessible.
- Increased Adoption in Healthcare: The application of DNA sequencing in personalized medicine, genetic testing, and diagnostics is expanding, enabling more targeted and effective treatments.
- Growing Research Investment: Governments, private institutions, and pharmaceutical companies are increasing their investments in genomics research, fueling demand for DNA sequencing technologies.
- Integration with AI and Big Data: The integration of artificial intelligence and big data analytics with DNA sequencing is improving data interpretation, accelerating discoveries, and advancing precision medicine.
- Cost Reductions: As sequencing technologies become more affordable, DNA sequencing is increasingly being used in clinical settings, further driving market growth.
- Expanding Applications: DNA sequencing is finding applications in areas like agriculture, forensics, and environmental science, broadening its market potential.
Regional Insights: Key Drivers of Growth in DNA Sequencing Markets

North America: Government Support Fuels Growth
North America was the leading region in the DNA sequencing market in 2023, driven by the presence of major industry players, increasing incidences of rare diseases and cancers, and advanced research and development facilities. The U.S. government plays a significant role in supporting DNA sequencing, with institutions like the National Human Genome Research Institute providing funding to research organizations. In August 2024, the U.S. FDA announced the use of whole genome sequencing to prevent foodborne illnesses globally. Additionally, Canada is investing $15 million over five years to create the Pan-Canadian Genome Library (PCGL), a national genomic data management system.

Asia-Pacific: Rapid Growth Through Investments and Collaboration
The Asia-Pacific region is expected to see the fastest growth in the DNA sequencing market. This expansion is driven by an aging population, demographic shifts, increasing investments, and favorable government policies. China’s Five-Year Plan (2021-2025) dedicates more than 10% of R&D investments to the biotech sector. India, a key player in the region, is seeing remarkable growth, with the Genome India Project completing the sequencing of 10,000 Indian genomes in March 2024. Over the past decade, India has become one of the top 12 bio-manufacturers globally, contributing to the region’s rising bio-economy.

Segmental Insights: Product, Technology and Application Trends
- Product Insights
  Consumables held the largest share of the market in 2023. This category includes reagents, buffers, and purification solutions, which are essential for DNA sequencing. The demand for genomics research and the growing affordability of consumables are driving the growth of this segment.
  The services segment is expected to experience the fastest growth, as sequencing services offer time savings and accuracy, with technical experts handling the experiments.
- Technology Insights
  Next-generation sequencing (NGS) dominated the market in 2023, thanks to its ultra-high throughput, scalability, speed, and broad applications. However, the third-generation sequencing segment is poised for the highest growth, due to its enhanced diagnostic accuracy and faster results compared to NGS.
- Workflow Insights
  The sequencing process, where nucleotides are read on a sequencer, was the leading workflow in 2023. The data analysis segment, which interprets the sequencing results using bioinformatics tools, is projected to grow rapidly, driven by innovations in software and user-friendly interfaces.
- Application Insights
  Oncology remained the dominant application of DNA sequencing in 2023, driven by the rising incidence of cancer and the increasing demand for early detection methods. DNA sequencing can even predict cancer risks in infants through genetic data. The consumer genomics segment is expected to grow the fastest, fueled by greater awareness about disease prevention, particularly for neonates, and the expanding application of genetic testing.
- End-Use Insights
  Academic research was the leading end-use segment in 2023, supported by increased funding from both government and private sectors, as well as frequent conferences and symposiums. The clinical research segment is expected to experience rapid expansion, benefiting from strong infrastructure, funding, and technical expertise.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/dna-sequencing-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5336

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
November 22, 2024
Cancer Biomarkers Market Trends, Growth and Key Insights (2024 – 2034)
Cancer Biomarkers Market Growth, Key Players and Trends

The global cancer biomarkers market, valued at US$ 30.39 billion in 2023, is projected to reach US$ 113.54 billion by 2034, growing at a CAGR of 12.73%. This growth is fueled by advancements in technology and the increasing use of artificial intelligence in oncology research and development.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5335

Cancer Biomarkers Market Overview

Biomarkers play a crucial role in healthcare by providing valuable insights into disease diagnosis, prognosis, treatment response, and personalized medicine. In particular, advancements in molecular biology for detecting tumor biomarkers have greatly enhanced personalized cancer care and improved patient outcomes. Over the years, the discovery of new, more sensitive, and accurate tumor biomarkers has steadily advanced, offering more precise options for cancer diagnosis and treatment.

Cancer Biomarkers Market Trends

In September 2024, the Breast Cancer Research Foundation (BCRF) made a historic investment of $70.3 million, the largest in its 31-year history, to support over 260 scientists at leading academic and medical institutions across 15 countries.
In February 2024, Pfizer Inc. and the American Cancer Society (ACS) launched “Change the Odds: Uniting to Improve Cancer Outcomes™,” a three-year initiative aimed at reducing disparities in cancer treatment. With $15 million in funding from Pfizer, the program focuses on improving cancer care outcomes in underserved areas of the United States.

Regional Insights

North America led the cancer biomarkers market in 2023 and is expected to maintain growth due to the rising cancer incidence and efforts by major players. The U.S. has seen a significant increase in cancer cases, particularly breast cancer, with 51,400 new non-invasive cases and 287,850 invasive cases estimated for March 2022. This surge will likely boost the use of cancer biomarkers in diagnosis. For example, in 2023, the U.S. DCCPS awarded nearly $580 million in grants, supporting global cancer research. Canada also invested $44.7 million in cancer research.

Asia Pacific is predicted to experience the fastest growth during the forecast period. Countries like India, China, and Japan are becoming key markets for cancer biomarkers due to the rising cancer rates and increasing demand for better diagnosis and treatments. India and the UK are collaborating on a £10 million project focused on affordable cancer treatments.

Segmental Insights
- Breast Cancer held the largest share of the cancer biomarkers market in 2023, with breast cancer cases projected to exceed 3 million by 2040.
- Genetic Biomarkers led the biomolecule segment, helping guide personalized treatment plans based on genetic alterations.
- Epigenetics is expected to grow the fastest, as FDA-approved epigenetic drugs show potential for cancer treatment.
- Diagnostics dominated the application segment, with biomarkers playing a critical role in early cancer detection, risk assessment, and treatment monitoring.
- Personalized Medicine is anticipated to grow rapidly, as biomarkers help tailor treatments to the individual genetic profile of tumors.
- Imaging Technologies held the largest share in the technology segment, offering non-invasive and effective methods for screening and monitoring tumors.
- OMICS Technologies are set to grow the fastest, enabling the discovery of numerous biomarkers through high-throughput analysis, advancing precision medicine.
Top Companies in the Cancer Biomarkers Market
- Abbott
- Sino Biological Inc
- Hologic, Inc
- Agilent Technologies
- Merck & Co. Inc
- F. Hoffmann-La Roche AG
- Illumina, Inc.
- Affymetrix Inc
- Thermo Fisher Scientific Inc
- QIAGEN
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/cancer-biomarkers-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5335

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
November 22, 2024
Central Lab Market Key Players, Trends and Future Outlook
Growth of the Global Central Lab Market Trends and Future Outlook

The global central lab market is projected to reach USD 3.46 billion in 2024 and is anticipated to grow to USD 6.04 billion by 2034, reflecting a compound annual growth rate (CAGR) of 5.71% over the next decade.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5038

Pharmaceutical Leaders Driving Growth in the Central Lab Market

A central lab, or central laboratory, is a specialized facility that conducts a wide range of laboratory tests and analyses. These labs play a crucial role in clinical trials, where they analyze samples such as blood, urine, and tissue collected from study participants. The primary aim of central labs is to provide accurate and consistent data across different study sites, which is essential for evaluating the safety and effectiveness of new drugs, medical devices, and other healthcare treatments.

To ensure high-quality results, central labs use advanced technologies and equipment, including automated systems for sample processing, high-throughput screening tools, and sophisticated analytical instruments. These labs are staffed by skilled technicians and scientists who perform tests and analyze the data.

While central labs are most commonly associated with clinical trials, they are also used for other types of testing, such as diagnosing infectious diseases or conducting genetic tests. These labs may be run by private companies, academic institutions, or government bodies, and are typically located in hospitals, research centers, or dedicated laboratory facilities.

Central Lab Market Trends
- Rising Number of Clinical Trials: The growing prevalence of chronic diseases and the surge in global research and development activities are driving an increase in clinical trials, which, in turn, is boosting the demand for central labs.
- Growing R&D Investments: Both government and private sector funding for research and development, as well as clinical trials, are significantly contributing to the expansion of the central lab market.
- Technological Advancements: Innovations like artificial intelligence (AI) and cloud-based technologies are transforming clinical research by automating and streamlining lab processes, making them more efficient and accurate.
Top Companies in the Central Lab Market
- ACM Global Laboratories: ACM Global Laboratories provides laboratory testing services for clinical trials and offers specialized expertise in the management of complex clinical trial testing. They focus on clinical pharmacology, molecular diagnostics, and infectious diseases, offering services across a global network.
- CIRION BioPharma Research: CIRION BioPharma Research specializes in offering bioanalytical services for pharmaceutical companies. They provide high-quality laboratory testing solutions, with a strong focus on biologics, small molecules, and biomarkers, ensuring the efficiency and accuracy of clinical trials.
- Eurofins Scientific: Eurofins Scientific is a global group offering laboratory services across a variety of industries, including pharmaceuticals. They provide comprehensive solutions for clinical trial testing, drug development, and regulatory testing, with a strong emphasis on precision, quality, and technological innovation.
- ICON plc: ICON plc is a global provider of outsourced development and commercialisation services to the pharmaceutical, biotechnology, and medical device industries. They offer laboratory testing as part of their clinical trial services and are renowned for their expertise in managing large-scale global trials.
- Intermountain Health: Intermountain Health is a non-profit healthcare system based in the U.S. that offers centralized laboratory services for clinical trials. They are known for providing comprehensive healthcare solutions and conducting medical research with a focus on innovation and patient care.
- IQVIA: IQVIA is a leading global provider of advanced analytics, technology solutions, and contract research services. Their central laboratory services support clinical trials with robust testing solutions powered by data-driven insights and cutting-edge technology to ensure faster and more accurate results.
- LabConnect: LabConnect offers global central laboratory services with expertise in clinical trials, providing testing solutions across a wide array of therapeutic areas. They are known for their high-quality service in managing complex clinical research projects.
- Labcorp: Labcorp is a prominent global life sciences company offering a broad range of laboratory services, including clinical trial testing. With a deep commitment to scientific research, Labcorp supports the entire clinical development lifecycle from early-stage research to commercialization.
- Medpace: Medpace is a global full-service clinical contract research organization (CRO) that offers central lab services, assisting pharmaceutical and biotechnology companies with clinical trials. Their services include laboratory testing, trial management, and regulatory compliance support.
- Reprocell: Reprocell is a global provider of laboratory services, with a focus on cutting-edge biotechnology, genomics, and cellular research. Their central laboratory services support clinical trials, with expertise in stem cell research and regenerative medicine.
- SGS S.A.: SGS S.A. is a leading testing, inspection, and certification company providing services to clinical trials through their central lab network. They offer reliable testing services for drug development, ensuring compliance with regulatory standards.
- Thermo Fisher Scientific: Thermo Fisher Scientific offers a comprehensive portfolio of laboratory services, including clinical trial testing, diagnostics, and specialized research. They are a leader in providing high-quality testing solutions powered by advanced technologies in the pharmaceutical and biotech sectors.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/central-lab-market

Access exclusive insight now @ https://www.towardshealthcare.com/price/5038

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
November 22, 2024
Global Clinical Trials Market Trends, Developments and Key Players
Clinical Trials Market Growth, Trends and Key Players

The global clinical trials market is valued at USD 54.39 billion in 2024 and is projected to reach USD 94.68 billion by 2034, growing at a compound annual growth rate (CAGR) of 5.7% during the forecast period from 2024 to 2034.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5018

Clinical Trials Market Trends

Rising Research and Development: The growing prevalence of chronic diseases and the increasing focus on areas like new drug discovery, personalized medicine, biologics, cell and gene therapy, and medical devices are driving the demand for clinical trials. This surge in research and development efforts is a key factor contributing to market growth.

Increasing Investments: Both government and private organizations are heavily investing in clinical trial projects, with many collaborating to accelerate growth in the field. These investments are crucial for supporting the advancement of clinical trials and the development of new treatments.

Supportive Government Policies: Governments worldwide are introducing policies and initiatives aimed at supporting clinical trials. These measures help to build scientific infrastructure, making it easier for trials to take place and for new treatments to reach the market.

Technological Innovations: New technologies are transforming the clinical trial process, making it faster and more accurate. These advancements streamline various aspects of trials, leading to improved efficiency and quicker results.

Clinical trials play a vital role in testing the safety and effectiveness of new drugs or medical devices for human use. They follow a structured process, typically divided into five phases, with each phase serving a specific purpose. A crucial aspect of clinical trials is determining which individuals can participate, ensuring that the results are both reliable and meaningful.

Beyond testing new drugs, clinical trials also explore other potential uses for existing treatments, such as making them more effective or reducing side effects. They also help identify the best ways to administer treatment to groups that haven’t been tested yet, like children.

Each clinical trial includes a detailed plan, outlining the procedures, tests, medications, and dosages involved, as well as the study duration. However, as the costs of drug development continue to rise, pharmaceutical and biotech companies are seeking more efficient ways to conduct trials. One growing trend is the outsourcing of clinical research activities to third-party organizations. By partnering with these service providers, companies can focus on their core activities while benefiting from specialized expertise. These providers now offer a wide range of services, from study design and preclinical evaluations to clinical trial management, safety data audits, and statistical analysis, making the process more comprehensive and cost-effective.

Recent Developments

In October 2024, the UK government launched the Voluntary Scheme for Branded Medicine Pricing, Access, and Growth (VPAG) initiative with an investment of up to £400 million. The scheme aims to improve access to and the efficiency of clinical trials, driving innovation and supporting the growth of the clinical research sector.

In January 2023, Paradigm raised $203 million in a fundraising round to enhance access to clinical trials. The funds will be used to expand the company’s platform and forge partnerships with healthcare systems and life science companies, ultimately improving the way clinical trials are conducted.

Clinical Trials Market Companies
- Parexel: A leading global provider of comprehensive drug development and regulatory consulting services. Parexel specializes in offering solutions for clinical trials, helping pharmaceutical, biotechnology, and medical device companies navigate the complexities of clinical research from the early stages to market approval.
- IQVIA: A global leader in advanced analytics, technology solutions, and contract research services. IQVIA leverages vast data sets and cutting-edge technology to support clinical trials, offering services that span clinical development, commercialization, and real-world evidence, ultimately driving innovation in healthcare.
- Charles River Laboratories: A prominent provider of laboratory services, offering solutions for the discovery, early-stage development, and commercialization of new therapies. Charles River specializes in preclinical and clinical research, supporting the biopharmaceutical industry with comprehensive drug development services.
- Omnicare: A healthcare services company specializing in pharmaceutical care for long-term care facilities, including clinical trials. Omnicare supports clinical research through services like patient management, medication adherence, and trial site services, assisting with regulatory compliance and research execution.
- Kendle: A global contract research organization (CRO) that provides a full range of clinical development services, from early-phase research to post-market services. Kendle focuses on accelerating the development of new therapies through its clinical trial expertise across various therapeutic areas.
- Chiltern: A global CRO that delivers high-quality clinical trial services, including clinical operations, regulatory affairs, and data management. Chiltern supports biotech and pharmaceutical companies in developing drugs by providing end-to-end solutions that help optimize the clinical development process.
- Pharmaceutical Product Development, LLC (PPD): A global provider of outsourced clinical trial services to the pharmaceutical, biotechnology, and medical device industries. PPD offers a range of services including clinical trial management, laboratory services, and patient recruitment to ensure the smooth execution of clinical studies.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/innovation-in-drug-development-calls-for-clinical-trials

Access exclusive insight now @ https://www.towardshealthcare.com/price/5018

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
November 22, 2024
Shedding Light on the Photomedicine Market Trends and Leaders
Exploring the Photomedicine Market Key Players, Innovations, and Expert Insights

The photomedicine market, valued at approximately $4.99 billion in 2023, is set to nearly double, reaching $10.22 billion by 2034. With a robust annual growth rate of 6.74% between 2024 and 2034, this field is gaining momentum as advancements drive its applications in oncology and dermatology. Growing awareness and the demand for non-invasive treatment options are key factors fueling its expansion.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5334

Photomedicine Market Overview

Photomedicine involves the use of photons to diagnose, treat, or manage medical conditions. This multidisciplinary field holds immense potential across various specialties, including surgery, cardiology, radiology, oncology, diagnostics, drug delivery, dermatology, and ophthalmology. Recent advancements in photomedicine have provided deeper insights into photodamage mechanisms, including the delayed formation of cyclobutane pyrimidine dimers (CPDs) and the physiological impact of visible light. These innovations continue to broaden the scope of photomedicine in modern healthcare.

Emerging Trends in the Photomedicine Market

The photomedicine market is witnessing transformative growth, driven by advancements in technology and increasing demand for non-invasive medical solutions. Key trends shaping the market include:
- Expanding Applications: Photomedicine is finding broader use in fields like oncology, dermatology, and ophthalmology, supported by innovations in laser and LED-based therapies.
- Focus on Personalized Treatments: Developments in photodynamic therapy (PDT) and light-based diagnostics are enabling tailored approaches to patient care.
- Integration of AI and Imaging: Artificial intelligence is enhancing photomedicine applications by improving diagnostic accuracy and treatment planning, particularly in imaging and radiology.
- Rising Awareness: Greater understanding of photodamage and its mitigation, such as the delayed formation of CPDs, is driving preventive and therapeutic strategies.
- Shift Toward Home-Based Solutions: Portable light-based devices are gaining popularity, empowering patients to manage conditions like skin disorders and chronic pain from home.
Leading Companies in the Photomedicine Market

The photomedicine market is supported by a range of innovative companies driving advancements in this dynamic field. Key players include:
- AngioDynamics Inc. – Known for its expertise in minimally invasive medical solutions, including laser and light-based therapies.
- Sisram Medical Ltd. – A global leader in energy-based medical devices, focusing on aesthetics and dermatology.
- Apax Partners LLP – An influential investment group backing healthcare innovations, including photomedicine technologies.
- Baring Private Equity Asia Limited – A prominent investor supporting growth in medical technology companies, including photomedicine pioneers.
- Biomedical Technology Holdings Limited – Specializes in developing cutting-edge photomedicine devices for various clinical applications.
- Koninklijke Philips N.V. – A global name in healthcare technology, offering solutions in imaging and light-based therapies.
- PhotoMedex Inc. – A major player in dermatology-focused phototherapy systems.
- Colorado Skin and Vein – A trusted provider of advanced light-based treatments for skin and vascular conditions.
- Thor Photomedicine Ltd. – Renowned for its innovative low-level laser therapy (LLLT) devices.
- Johnson & Johnson MD&D – A key contributor to medical device advancements, including photomedicine applications.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/photomedicine-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5334

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
November 22, 2024
Cord Blood Banking Services Market Trends and Growth Outlook
Cord Blood Banking Services Market Companies, Strategies and Developments

The cord blood banking services market, valued at approximately USD 33.9 billion in 2023, is projected to expand to USD 65.36 billion by 2034, reflecting a compound annual growth rate (CAGR) of 6.15% from 2024 to 2034. Key growth drivers include the rising prevalence of chronic disorders, advancements in research and development, and increasing awareness about the benefits of cord blood banking.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5333

Cord Blood Banking Services Market: Securing the Future

Cord blood, collected from the umbilical cord and placenta after a baby’s birth, is a rich source of stem cells capable of treating various medical conditions. Cord blood banking services encompass the collection, processing, and storage of these valuable stem cells in either public or private banks. Public cord blood banks make donated stem cells available for anyone in need, while private banks reserve them exclusively for the donor’s family.

The demand for stem cells is driven by the increasing prevalence of cancer, genetic disorders, infectious diseases, hematological issues like anemia, and immune system disorders. Growing awareness of cord blood donation is further fueling the market’s expansion.

Cord Blood Banking Market Trends

Several recent developments are shaping the cord blood banking landscape:
- In September 2024, Cordlife Group launched an upgraded processing and storage facility in Singapore, featuring advanced laboratory monitoring systems to enhance cord blood banking operations.
- In July 2024, NMDP Biosciences partnered with the Cord Blood Bank Alliance to provide pre-identified cord blood units optimized for manufacturing cell therapies, particularly those derived from natural killer (NK) cells.
- In May 2024, the Department of Health (DOH) and M42 established the Abu Dhabi Biobank, the largest hybrid cord blood bank in the region, aiming to improve therapeutic access, reduce treatment wait times, and enhance patient outcomes.
Segmental Insights
- Private Cord Blood Banks dominated the market in 2023. These banks provide exclusive storage for families, allowing stem cells to be used without compatibility testing.
- Public Cord Blood Banks are expected to grow rapidly due to their affordability, adherence to FDA regulations, and growing awareness about their benefits.
- The Cord Tissue Segment led the market in 2023, with its mesenchymal stem cells offering regenerative potential for various conditions.
- The Cord Blood Segment is poised for significant growth as the U.S. FDA recognizes its effectiveness in treating over 80 conditions.
- In applications, the Diabetes Segment dominated in 2023, with research highlighting stem cells’ potential to balance the immune system and support diabetes management.
- The Cancer Segment is expected to see rapid growth, driven by rising cancer cases and the demand for innovative treatment approaches.
Leading Companies in the Market
- Americord Registry
- Babycell
- BioLife Solutions
- Cordlife Group Limited
- Cryo-Cell International, Inc.
- Cryoviva
- FamiCord Group
- LifeCell International
- Medipost
- NMDP Biosciences
- StemCyte, Inc.
- ViaCell, Inc.
Insights from Industry Leaders

Mayur Srisrimal, CEO of LifeCell International, India’s largest cord blood bank, highlighted the growing adoption of cord blood banking in India. He noted that hybrid banking models, which balance accessibility for families and donors, are gaining traction, alongside more affordable pricing plans.

Recent Innovations
- In October 2024, researchers at Cordlife Group Limited developed machine-learning models to optimize cord blood unit selection, improving transplantation outcomes.
- In March 2023, a team at New York Presbyterian Hospital achieved a breakthrough by using cord blood stem cells to put the first mixed-race female HIV patient into remission, showcasing the transformative potential of cord blood in treating complex diseases.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/cord-blood-banking-services-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5333

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
November 22, 2024